Ava Begley’s parents say they feel “deeply grateful” that the researchers, from 91ֱ�� University NHS Foundation Trust (MFT) and The University of Manchester (UoM), have made this discovery, which is one of the most common genetic causes of severe epilepsy.

Delivered through the this groundbreaking work is already transforming the lives for many children and young people around the world, providing long-awaited answers and hope for the future.

Ava’s parents, Daniel Begley and Elizabeth Dowd, from Sydney, Australia, said: “Our first reaction was a mixture of emotion – relief at finally having a diagnosis, but also sadness in understanding the seriousness of the condition and how rare it is. Above all, we felt grateful that Ava’s experience may contribute to greater knowledge and future progress and treatment.”

This new condition, which the researchers have named as “Recessive RNU2-2-related neurodevelopmental disorder”, results in difficult-to-control seizures and severe developmental delays in children, often appearing within their first year of life.

Published in the journal , the research has so far identified 84 individuals living with the new condition, while experts estimate that thousands more remain undiagnosed across the world.

The team estimates that millions of people globally could be ‘carriers’ of the faulty gene behind this disorder.

91ֱ�� lead and first author of the paper Dr Adam Jackson, Academic Clinical Fellow at the 91ֱ�� Centre for Genomic Medicine, part of MFT, and The University of Manchester, explained: “We believe that as many as in 1 in 100 people could unknowingly be carriers of this condition. If both parents are carriers, there is a 1 in 4 chance with every pregnancy that their child could be affected. We estimate roughly 1 in 40,000 people may be living with this condition, making it one of the most common neurodevelopmental disorders currently known. Our discovery brings hope for many patients and families who have been searching for answers and is already having a positive impact around the world.”

This major advance builds on in which they showed the importance of the RNU genes in brain development and function.

The research team made the new discovery by analysing changes in several hundred RNU genes in data of individuals who took part in the 100,000 Genomes Project, a Genomics England initiative to sequence and study the role genes play in health and disease.

Dr Jackson, who is also an early career researcher in the NIHR 91ֱ�� BRC’s Rare Conditions Theme, explained: “What makes this discovery even more remarkable is that RNU2-2 is extremely small in comparison to other genes. Unlike most other genes, RNU2-2 does not even make a protein. We were astonished to discover how changes in this tiny gene can have such profound effects in so many individuals.”

Children with the condition experience severe early on in life, often in their first year. This means they have seizures – sudden surges of electrical activity in the brain which can cause the body to stiffen, jerk, shake and lose consciousness. These seizures can be difficult to fully control with medication, highlighting the urgent need for improved therapies.

The condition also has a profound impact on brain development, causing delays or inability to achieve key milestones such as walking or talking. Almost all affected individuals have significant learning problems.

Ava’s story

6-year-old Ava has lived with complex neurological symptoms from early childhood and requires full-time care and ongoing medical support.

Ava’s condition includes developmental delay, profound intellectual disability and severe epilepsy with frequent seizures. She would often experience 100 to 200 seizures per day, but these are now more controlled with medication.

Ava is non-verbal and cannot communicate through speech or gestures. She requires full-time support with daily life, including bathing, toileting and feeding. She also experiences major motor and balance difficulties, can only walk short distances and falls frequently. Ava often bites and pulls hair out and screams in frustration.

Collaborating with 91ֱ�� researchers, the Sydney Children’s Hospital Clinical Genetics Team who support Ava and her family, were able to link Ava’s condition to the newly identified recessive RNU2-2-related disorder.

Ava’s dad, Daniel and mum, Elizabeth, said: “Ava is a beautiful little girl with a bright presence. She loves looking through books, music, sensory play, being outdoors, and spending time with her family. Even with the immense challenges she faces, Ava brings extraordinary love and meaning into our lives. She has a deep presence about her that touches everyone who meets her.

“For many years we have been through extensive medical investigations, specialist appointments, and genetic testing, hoping to find an answer that could explain Ava’s condition and guide her care. Like many rare disease families, we have lived with a long period of uncertainty.

“Having a diagnosis is incredibly meaningful. It gives Ava a name and a place in the medical world, rather than being an unanswered mystery. It helps us feel that we are getting closer to the starting point of being able to find a cure/treatment, and provides hope that research and awareness may lead to better understanding and support in the future.

“We believe that rare disease research is vital, not only for families like ours, but for the broader medical community. Ava’s journey has been challenging, but she is deeply loved, and we are committed to advocating for her and for all children living with rare and complex conditions.”

91ֱ�� lead and senior author Consultant Clinical Geneticist at the 91ֱ�� Centre for Genomic Medicine at MFT, Professor of Genomic Medicine and Rare Diseases at UoM and Rare Conditions Theme Co-Lead at the NIHR 91ֱ�� BRC said: “Our work helps expand knowledge of conditions related to RNU genes, an emerging group of diseases which potentially affect around 1 in 10,000 individuals globally. It also shines a light on the regions of the human genome sometimes dismissed as ‘junk DNA’. We now see that so-called ‘dark regions’ are vital for health.”

Prof Banka, who is also Clinical Director of the , a virtual centre based at MFT which aims to improve the lives of people with rare conditions, added: “At MFT, we have established a dedicated RNU clinic to identify and support more patients with these conditions. Looking to the future, this discovery paves the way to help unlock life-changing treatments for the recessive RNU2-2-related neurodevelopmental disorder.”

Professor Marian Knight, Scientific Director for NIHR Infrastructure, said: “Discovering the cause for conditions like Ava’s is the first step to personalised treatment and improved lifelong health and quality of life. This breakthrough is a testament to the robust research infrastructure the NIHR has developed over the last 20 years, enabling us to turn world-class genomic science into better care.”

• The paper 'Biallelic variants in RNU2-2 cause a remarkably frequent developmental and epileptic encephalopathy is published in DOI: . 

A team of cancer genomics* scientists from The University of Manchester and The Institute of Cancer Research, London, forensically examined the genetic make-up of tumours in 16 different cancers. Their findings, which have been published in , are the culmination of six years’ of research and could significantly increase the number of cancer patients eligible for targeted and immune-based treatments. 

This landmark study was co-led by Professor David Wedge at the 91ֱ�� Cancer Research Centre and Professor Richard Houlson from The Institute of Cancer Research. It used whole-genome sequencing data from nearly 11,000 NHS patients with cancer, and is part of Genomics England’s 100,000 Genomes Project, which is the largest single genomics study for cancer ever to be undertaken worldwide. 

The researchers analysed hundreds of millions of mutations in 11,000 tumours which covered the whole genome of a human being which consists of more than three billion bases and includes around 20,000 genes. From this they were able to identify the most comprehensive map to date of genetics ‘scars’ left behind in cancer DNA. 

In total the team of ‘data detectives’ catalogued 370 million mutations and assigned them to 134 distinct mutational ‘signatures’ which are patterns of DNA damage that act like fingerprints of the processes that caused the cancer. Of these, 26 signatures were not previously included in the database of known signatures used by many scientists. 

The most significant finding was that many more patients may benefit from precision therapies than currently recognised. The study identified large numbers of tumours with evidence of homologous recombination deficiency (HRD) which is a weakness in DNA repair that makes cancers vulnerable to PARP inhibitors and platinum-based chemotherapy. HRD was identified in 16% of breast cancer tumours and 14% of ovarian cancer tumours, so based on UK figures, researchers estimated that more than 7,700 breast cancer patients and over 1,000 ovarian cancer patients in the UK could benefit from HRD-targeted therapies which is much greater than are currently identified through standard genetic testing for mutations in genes such as BRCA1/BRCA2 alone. 

This study also supports the growing theory that toxins produced by particular strains of E. coli in the gut could be the potential cause of the rise in early-onset bowel cancer in younger people. The team found this signature occurs more in younger patients than older patients, in contrast with several other signatures that tend to increase with a patient’s age. 

, professor of cancer genomics and data science at The University of Manchester said: “Every cancer develops because DNA is damaged over time. Different causes such as ultraviolet light, tobacco smoke or inherited gene faults leave different patterns in the genome. By reading these patterns we can now understand, in a larger proportion of cancers, what caused the cancer, when key mutations occurred, and which treatments are most likely to work.

“Until now, most testing has focused on mutations of a single base (or ‘letter’) in a cancer’s DNA. By analysing the entire genome and examining more complex mutations that affect multiple bases, I hope our research contributes to better predictions of which treatment might benefit specific patients. This could enable better targeting of treatment to those patients most likely to benefit, given the genetic make-up of their tumours.”

Professor Richard Houlston, head of cancer genomics at The Institute of Cancer Research, London, said: “The scale of this study was very large, as we analysed samples from almost every tumour type. The quantity of data was enormous, and although laborious to work through, we have been rewarded with a very exciting outcome. This study provides one of the clearest demonstrations yet that reading the full genetic history of a tumour can unlock clues to better patient care.  The future of cancer treatment lies not just in finding mutations, but in understanding the story they tell.”

Professor , Director of the 91ֱ�� Cancer Research Centre, a partnership formed in 2006 by The University of Manchester, Cancer Research UK and The Christie NHS Foundation Trust said: “This remarkable and comprehensive study demonstrates how 91ֱ�� is leading the charge in the field of big data genomics. The world-class research coming out of the Wedge lab is pioneering, and will transform our understanding of the human genome and the potential for better cancer treatments for our patients.”

The study is supported by the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre. 

* cancer genomics is the study of genetic changes in cancer cells to understand tumour development, progression and to guide personalised treatment.

• The study a Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types is published in https://doi.org/10.1038/s41588-025-02474-x

Building on existing collaboration, the partnership aims to address both immediate and longer-term challenges across the water industry, including climate resilience, water quality, wastewater management and resource optimisation.  

The partnership comes at an important time for the sector, as it undergoes rapid transformation in response to climate change, population growth, and an evolving policy and regulatory environment. The University will support this challenge by providing research-driven solutions that support water quantity and quality for communities and the environment.

Under the MoU, the University and United Utilities will expand engagement across strategic innovation priorities, aligning academic expertise with company needs and opportunities, to deliver tangible, real-world impact.

On a visit to the University, the group toured the robotics lab based in the University’s flagship engineering building, observing some of the cutting-edge robotics equipment that is being developed for real-world applications.

Recent collaborative projects between the two organisations include the use of robotics for water network inspection, and a digital twin for the GMCA Integrated Water Management Plan.

Sarah Sharples, Vice President and Dean of the Faculty of Science and Engineering, said: "This partnership marks an important step in uniting academic excellence with industry expertise to address the evolving challenges of the water sector. Together, we aim to drive innovation opportunities that benefit students, research, and society."

Dr Louise Bates, Director of Business Engagement and Knowledge Exchange at The University of Manchester, said: “Collaboration between The University of Manchester and United Utilities dates back to 2006, and in recent years it has really grown through joint research and student-focused activities. This has created a strong foundation for us to build on through this new Memorandum of Understanding.” 

Jo Harrison, Director of Asset Management at United Utilities, said: “We are passionate about securing resilient services for the North West, both now and for the future.

"This partnership builds on a strong foundation of collaboration and gives us an exciting opportunity to bring together world-class academic insight with practical, real-world experience. By combining our strengths, we can make a meaningful and lasting difference on the ground, helping to deliver a stronger, greener and healthier North West for generations to come.”

Solving mechanistic models of natural environments is notoriously time‑consuming and often unstable under diverse real‑world conditions. To overcome this, the team trained AI “emulators” to reproduce the behaviour of an existing mechanistic model that describes carbon cycling in ocean sediments. Once trained, these emulators could then be applied globally to predict dissolved organic carbon behaviour at a resolution and scale that were not feasible using the original numerical model alone.

The study reveals that 11% of the particulate organic carbon arriving at the seafloor is returned to seawater as dissolved organic carbon, while 24% is sorbed onto minerals. Strikingly, about half of all solid‑phase organic carbon in the upper metre of marine sediments appears to originate from dissolved carbon that has been sorbed onto minerals. These findings provide the first global quantification of dissolved organic carbon cycling within sediments and highlight its significance within Earth’s long‑term carbon budget.

In developing the modelling framework, the researchers compared deep learning architectures, random forest models and simpler feedforward artificial neural networks. Unexpectedly, the simplest algorithms produced the most accurate predictions. The team confirmed these results by validating emulator outputs against low‑resolution global maps—where the mechanistic model could still be solved numerically—and against algebraic solutions for variables with known analytic expressions. They also found that increasing the complexity of the neural network structures consistently reduced prediction accuracy, offering rare empirical support for the Principle of Parsimony, also known as Occam’s Razor, within AI model development.

These insights have important implications for climate science. Quantifying carbon budgets across the sediment–water interface is essential for understanding global climate dynamics but has historically been hindered by computational limitations. By providing a fast, scalable and accurate way to represent sediment carbon processes, the new AI‑based framework can be integrated into global circulation models and used to explore potential ocean‑based climate change mitigation strategies. The research opens new avenues for simulating and testing how marine carbon reservoirs may respond to environmental change in the coming decades.

Read further papers related to this research:

• Preservation of organic carbon in marine sediments sustained by sorption and transformation processes
  DOI:
• Potential use of engineered nanoparticles in ocean fertilization for large-scale atmospheric carbon dioxide removal
  DOI:
• Long-term organic carbon preservation enhanced by iron and manganese
  DOI:

Sending waste to landfill generally produces the highest levels of net greenhouse gas emissions of any waste treatment option. While it’s a common belief that anything placed in a ‘black bag’ or general waste bin ends up in landfill, this isn’t always the case; landfill plays a much smaller role in the UK waste industry than it used to – and has been eliminated on campus in relation to the University’s two main waste contracts.

Instead of landfill, the University’s non-recyclable general waste now goes through a process known as Energy from Waste (EfW), a waste management method that converts non-recyclables into electricity and heat. Once waste is collected on campus, it is transported to a waste transfer station nearby, where it is ‘bulked up’ before being sent to an EfW facility.

At the EfW facility, it is burned under safe and controlled conditions. The process of burning the waste generates heat, which is then used to power steam turbines and produce electricity, ensuring that every by-product (which includes ash and metals) is recovered and reused, meaning nothing goes to landfill.

The University will remain committed to creating a sustainable campus, by looking at reducing waste to keep products, parts, and materials in use for as long as possible, to strengthen its circular economy.

Sarah Choi, Environmental Sustainability Manager, said: "Achieving Zero Landfill shows what's possible when we work together to align our processes with our sustainability goals. It's a huge step in our environmental ambitions and strengthens our commitment to create a more circular, responsible campus."

The University has a commitment to be zero carbon by 2038, and last year began powering its campus with clean, renewable electricity from a major new solar farm. The University ended all investments in fossil fuels in 2022.

To find out more about this and other commitments around waste, transport and nature, visit the Sustainability website.

The Connect & Contribute Mentoring Scheme matches students studying on one of the University of Manchester’s Education programmes with teenagers who are thinking of applying to university but are unsure of whether higher education is for them. Under the scheme Year 12 students at Cheadle Hulme, Didsbury and Trinity High Schools have been matched with university students, most of whom are in their early 20s and many of whom are from overseas. 

Dr Rui He, Senior Lecturer in Education and Dr Alex Baratta, Reader in Language and Education at the University of Manchester have helped to set up the scheme. Dr He explains: 

“Connect & Contribute matches local sixth form pupils who are in the first year of studying for their A Levels with students who are already in higher education.  

“The scheme allows young people who are considering applying for university, but may be the first person in their family to do so, to connect with someone who is currently attending university. Many of our students have travelled to the UK to continue their postgraduate qualification having already completed a degree in their home country, so can also give information and reassurance about moving away from home. 

“We’ve found that by offering young people the opportunity to have structured but informal conversations with someone who is fairly close to them in age we can build their confidence in applying to university. We can also provide practical information on the sort of details to include on university applications and on potential career paths.” 

The Connect & Contribute Scheme, which is supported by Social Responsibility Catalyst Fund from the School of Environment, Education and Development within the University of Manchester, is now in its second year.  

One young person who was mentored in the first year of the scheme said:  

“It has been interesting and helpful discussing university topics, especially with a student who has experience in university life.” 

Another commented: 

“I still feel overwhelmed about going to university and living all by myself, but the meeting encouraged me to accept changes with a positive mindset.” 

A MA Digital Technologies, Communication and Education degree student who was one of the scheme mentors said: 

“I had the privilege of supporting Year 12 students from nearby secondary schools, helping them build confidence and offering insights into university applications, student life, and the overall university experience. It’s been a truly rewarding experience to share my journey and offer guidance to students exploring their academic futures.” 

Sixth form students who were mentored in the first year of Connect & Contribute will be sitting their A Levels this year and it’s hoped that many of them will be on their way to university, with some of them possibly set to become University of Manchester students in 2026-27.

The recovery plan launched in January 2023 after one of the most testing years in NHS history with a perfect storm of pressures resulting in overwhelmed A&E departments, and significant numbers of patients waiting over 12-hours for beds.

Using national performance data, the 91ֱ�� team show that initial improvements in the 4-hour and 12-hour waiting time targets and in the category two ambulance response times were achieved in the 12 months after the plan was announced. These initial performance improvements have since plateaued.

said: “A core aim of the recovery plan was to bring people together to coordinate a unified whole system response to tackle urgent and emergency care performance. This has happened – though the complexity of meeting national targets, addressing local challenges and responding to rising demand means that many systems have been running to stand still.”

The recovery plan set out a number of ambitions, including:

• Improve to 76% of patients being admitted, transferred or discharged within four hours by March 2024.

• Improve ambulance response times for Category 2 incidents to 30 minutes on average over 2023/24.

During the period the recovery plan was implemented, the trend of declining performance for 4-hour waits and 12-hour waits was arrested, and performance improved across 4-hour waits, 12-hour waits and Category 2 ambulance response time between February and September 2023.

However, following September 2023, initial rates of improvement were not maintained across the different indicators, and performance plateaued. The findings demonstrate that meaningful improvement towards the set targets takes time to deliver, especially in the context of rising volumes in ED, experienced over this period.

The 91ֱ�� team found that successful and sustainable change depends not only on service developments but also on three broad enablers - improved communication, partnership working, and visible and present leadership - identified via in-depth key informant interviews conducted as part of the evaluation.

said “Our real-time evaluation of the impact of the 2023 recovery has provided crucial insights that have informed current and future winter planning. This demonstrates the value of NIHR’s investment in independent, rapid and responsive evaluation to inform decision-making and future service delivery.”

The report Independent evaluation of the 2023-2025 NHS Delivery Plan for Recovering Urgent and Emergency Care Services, including prioritisation of the high-impact initiatives is available .

Professors , , , ,  and have all been awarded what is regarded as one of the highest honours for health and social care researchers in the UK.

Senior Investigators are among the most outstanding and influential researchers funded by NIHR. They are recognised for the quality and global reach of their research. They also help mentor the next generation, strengthen research culture and embed inclusion.

, is Professor of Critical Care Medicine, Vice Dean for Health and Care Partnerships and Research Professor at the Humanitarian and Conflict Response Institute at The University of Manchester.

He is also a Critical Care Consultant at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust and based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

He said: “I am delighted to be appointed as a NIHR Senior Investigator for a second term. This national award will allow me continue to provide a systems voice from Greater 91ֱ�� to help influence national research policy in applied health, social care, and public health, and to act as an international ambassador for the National Institute of Health and Care Research."

is the first ever NIHR Research Professor in Digital Mental Health in the UK and a Professor of Clinical Psychology at The University of Manchester. 

She co-founded spinout company CareLoop Health, a UK digital therapeutics company developing AI-powered tools to monitor symptoms, predict relapse, and deliver personalised care for people with severe mental illnesses like psychosis.

She is also based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

She said: “This NIHR Senior Investigator award will provide an important platform to advance my research in digital mental health and to strengthen the evidence base for innovative approaches that improve care for people with severe mental health problems. I hope it will support closer partnerships with service users, clinicians and services, and help drive research that delivers meaningful impact in routine practice.”

' research focuses on Data Science and Health Services using large-scale primary care databases. 

He is an expert in  computational statistics and machine learning  and has a long track record in research using large-scale primary care and other administrative databases to investigate quality of care, mortality and cardiovascular disease, with a focus on the effects of policy changes and the role of socio-economic and regional disparities

He said: “I’m delighted to receive this NIHR Senior Investigator award. It recognises the collective efforts of my collaborators and provides an exciting opportunity to accelerate our work using real‑world health data to improve the quality and equity of care. This support will help us drive forward innovative, policy‑relevant research in primary care and population health, ensuring it has the greatest possible benefit for patients and communities.

is Professor of Rheumatology at The University of Manchester and Honorary Consultant Rheumatologist at 91ֱ�� Royal Infirmary, part of Manchester University NHS Foundation Trust.

Prof Buch is also Chief Investigator for the Medical Research Council (MRC) and British Heart Foundation UK CARDIO-IMID Partnership and Chair for the MRC-NIHR 'Efficacy, Mechanism, Evaluation' Programme.She is also based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

She said: "I am delighted to be re-awarded the NIHR Senior Investigator Award. This award strengthens my ongoing commitment to advancing research that improves outcomes for people living with rheumatic and musculoskeletal diseases. I warmly welcome this support, which will help advance our scientific goals, foster meaningful collaboration and help translate innovative discoveries into real-world clinical benefit"

is Professor of Psychiatry and Director of Global Mental Health Research at The University of Manchester and Director of the Global Centre for Research on Mental Health Inequalities and an Honorary Consultant at Mersey Care NHS Foundation Trust.

He is also based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

Professor Lucy Chappell, Chief Executive Officer of the NIHR and Chief Scientific Adviser at the Department of Health and Social Care, said: “By recognising leaders across the breadth of health and care, we are reinforcing NIHR's commitment to supporting excellence wherever it is found and ensuring that research leadership mirrors the communities and professions it serves.

“Senior Investigators make a significant impact to the NIHR and the wider research landscape and I look forward to seeing the contributions and impact they make across health and care research.”

Researchers are awarded Senior Investigator status based on their contributions to the NIHR and their leadership of high-quality, internationally recognised research.

As outstanding leaders of patient and people-based research, NIHR Senior Investigators serve on NIHR funding committees and boards and provide leadership at a regional or national level.

They serve as NIHR ambassadors, demonstrate research excellence, contribute to national growth, and champion the involvement of patients and communities into research.

Hosted by 91ֱ�� Metropolitan University, in partnership with The University of Manchester, Greater 91ֱ�� Combined Authority (GMCA), The Growth Company, and University of Salford, the flagship Made in Greater 91ֱ�� event demonstrated how coordinated regional action is accelerating delivery of the Government’s Modern Industrial Strategy.

Recent national data shows that Greater 91ֱ�� is the UK’s fastest growing city region, with productivity growth outpacing national averages for more than a decade.

The city region has long been recognised as a testbed for the future UK economy, bringing together universities, business and civic partners to tackle national challenges at regional scale.

That collaborative model now supports Greater 91ֱ��’s approach to good growth, as it leads the UK’s ambitions in – advanced materials and manufacturing; creative industries; digital, cyber and AI; health innovation and life sciences; and low carbon.

These are aligned to five of the sectors identified as having the greatest potential for growth in the Modern Industrial Strategy.

Professor Steve Rothberg, Provost and Deputy Vice-Chancellor at 91ֱ�� Met, said: “With universities acting as powerful anchor institutions for growth, there has never been a more important time to connect, collaborate and drive collective impact.

“Here in Greater 91ֱ��, we have a long tradition of being at the forefront of innovation. This event was a fantastic opportunity for organisations across the city-region to come together and re‑emphasise this commitment while exploring future ways to deliver for the UK.”

Speakers at the event outlined how universities, industry and civic partners are aligning investment, skills pipelines, research strengths and business support to accelerate the industrial strategy in real time.

By uniting academic expertise, cutting edge R&D facilities, industry ambitions and civic leadership, Greater 91ֱ�� is building the environment required for long term national competitiveness.

Professor John Holden, Vice-President for Civic Engagement and Innovation, said: "Yesterday’s Made in Greater 91ֱ�� event showed exactly what our city‑region does best by bringing universities, industry and civic partners together to drive innovation. Our universities must ensure that innovation fuels growth that is fast, ambitious and inclusive so the benefits of our progress as a region are shared across every community.

"Through the University’s innovation arm, Unit M, we are partnering with the Industrial Strategy Advisory Council to ensure this collaboration shapes national priorities. Our recently launched deep tech accelerator is a demonstration of a cross-Greater 91ֱ�� initiative with shared purpose and dedicated resources to boost innovation. 

"We are also working with GMCA and Rochdale Development Agency to scope out the next phase of development of the Sustainable Materials and Manufacturing Centre (SMMC), the first major development in the Atom Valley Mayoral Development Zone. Through the Cambridge x 91ֱ�� Partnership we’re proving that our ambition and impact extends well beyond the region, strengthening national capability through collaboration between two of the UK’s most globally recognised innovation ecosystems."

Speaking at the event, Jo Ahmed MBE, Practice Senior Partner at Deloitte, said: “What we do brilliantly in this city region is that we come together across the public and private sectors and academia to deliver impact and, importantly, to deliver action.

“When I speak to national and international colleagues, they all want to know what it is we are doing in Greater 91ֱ�� to create the growth we are seeing here. My answer is that it’s a blend of the spirit this place, it’s how we connect, how we collaborate, and how we support each other for collective long term growth and opportunity.

“I am truly optimistic about the future opportunities that can be delivered through a continued place-based approach to deliver the Modern Industrial Strategy and Greater 91ֱ�� Sector Development Plans, and to continue that collaboration between sectors to benefit the broadest possible cross section of businesses and the communities around us.”

Current drug delivery methods often struggle to target anti cancer treatments precisely at tumour sites, leading to unwanted effects elsewhere in the body. 91ֱ��’s snail inspired robots aim to change this by delivering therapies only where they are needed, with highly targeted, region-specific precision.

By reliably anchoring themselves within malignant tissues and releasing their therapeutic cargo in a controlled manner, the robots are expected to increase drug bioavailability at tumour sites, significantly reduce off target toxicity and improve patient outcomes.

The project – funded through UKRI’s Cross Research Council Responsive Mode (CRCRM) scheme, which supports emerging research that transcends disciplines – aims to transform colorectal cancer treatment by enabling highly targeted drug release directly at tumour sites.

Drawing inspiration from the slow, controlled and highly adaptable movements of snails and slugs, the research team will mimic the animals’ unique slime based locomotion, powered by rhythmic muscular waves and adhesive mucus, to engineer mini robots capable of navigating the gastrointestinal tract with exceptional accuracy.

Snail locomotion has long intrigued evolutionary biologists and roboticists, but its biomechanics remain under explored. This project will generate the first high resolution experimental datasets on snail movement, mucus interactions and foot actuation, enabling the team to build advanced digital simulations and machine learning driven control systems.

These biological insights will underpin the design of a new class of biocompatible soft robots, constructed from peptide based bionanomaterials that can be finely tuned at the molecular level. Engineered to respond to benign external triggers such as magnetic fields, the materials will enable non invasive, remote control of the robotic devices once inside the body.

The project will also create a multiscale digital twin simulation framework, integrating biomechanics, robotics, bionanomaterials and cancer biology. This virtual testing environment will accelerate design optimisation, reduce laboratory costs, and allow researchers to model robot–tissue interactions before clinical translation.

While the primary goal is to deliver advances in colorectal cancer treatment, the technology has potential applications far beyond oncology. The soft robots could serve as alternatives to capsule endoscopy, offer new solutions for environmental and industrial microrobotics, and enable safer operation in complex environments - from pipe inspection to sustainable agri food systems.

The project reflects The University of Manchester’s leadership in engineering biology and its commitment to pioneering research with real world health impact.

Read further papers related to this research:

• Charge Directed Selective Co‐Assembly of Ionic Complementary Peptide Binary Mixtures
  DOI:
• Harnessing 3D microarchitecture of pterosaur bone using multi-scale X-ray CT for aerospace material design
  DOI:
• Scalability of resonant motor-driven flapping wing propulsion systems
  DOI:
• The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion
  DOI:
• Energy and time optimal trajectories in exploratory jumps of the spider Phidippus regius
  DOI:

The study found SEND complaints make up 27% of the complaints received by the LGSCO and 48% of the cases that it upholds. Common issues include delays in carrying out Education, Health and Care Plan (EHCP) assessments, and failures to deliver the support children are legally entitled to.

Despite these challenges, the research also points to the impact of the Ombudsman’s work. Its recommendations can help councils identify problems, strengthen accountability, and push for improvements that benefit families.

In some cases, the findings have empowered local officials to argue for more resources or rethink how services are delivered - however, the report also highlights limitations including the time and capacity required to respond to investigations, and repeated recommendations on issues councils recognise but lack the means to resolve.

A key gap identified is that the Ombudsman cannot investigate complaints directly against schools - even though they play a central role in delivering SEND support - which can leave families without clear routes to resolve issues.

The report sets out recommendations to strengthen the system, which include extending the Ombudsman’s powers to cover schools, raising awareness of joint investigations with health bodies, and improving communication between councils and the Ombudsman. Crucially, it emphasises that meaningful reform must address underlying pressures on the SEND system, including funding shortages and workforce gaps.

“This research comes at a key moment for SEND system reform,” said Ash Patel, Programme Head for Justice at the Nuffield Foundation. “The Government’s intention to improve complaints and mediation processes - enabling faster and more collaborative, resolution of disagreements and reducing the need for appeals to the SEND Tribunal - is welcome. However, the proposals are silent on the role of the LGSCO, and it remains frustratingly unclear how disputes will be avoided or how routes for appeals and complaints will operate.”

“The report points to high levels of tension between the education system and families of children with SEND; without greater attention to minimising these conflicts, it is difficult to see how existing pressures on complaints and appeals will ease.” 

It follows a campaign led by a national coalition of partners, including academics from The University of Manchester, and  legal representatives from Garden Court Chambers and Bhatt Murphy Solicitors, who challenged the previous policy framework.

The rules, which affect asylum seekers who have waited 12 months or more for a decision on their initial claim, come into effect on 26 March 2026.

The previous policy restricted asylum seekers to occupations on the Immigration Salary List, excluding most health professions, including doctors and nurses.

One of the leading voices in the campaign was the Refugee and Asylum Seekers Centre for Healthcare Professionals Education (REACHE), directed by, Dr Aisha Awan, a Senior Clinical Lecturer at The University of Manchester and Northern Care Alliance NHS Foundation.

Displaced clinicians at REACHE receive specialist language, clinical and acculturation training alongside strong pastoral support, enabling them to secure regulatory registration and safely return to practice within the NHS.

The policy change follows legal proceedings which highlighted that highly qualified, NHS-ready clinicians were unable to work in shortage specialties despite clear workforce need.

Dr Awan said: “As we continue to witness increasing displacement of people by conflict and global events, we must ethically address that doctors, nurses and health professionals becoming deskilled is a huge loss to humanity.

“Alongside being economically counterproductive, undermining NHS workforce capacity and negatively impacting mental health and integration.

“At a time of increasingly hostile rhetoric around migration, it’s been important to show the impressively positive impacts of this programme on the NHS and patients.

 “I’m immensely  proud to be part of our University which supports this sort of positive and impactful change. Our success demonstrates how evidence, persistence and coalition-building can influence systems, no matter how big the resistance to change.”

Undergraduate students from the University’s school of Law, Medicine, Computer Sciences and Languages were involved in the Interfaculty Service Learning project, attending the judicial review hearings.

Maria-Ioana Dicu a second year computer science undergraduate, was one of the undergraduates  to observe how research, evidence and advocacy connect within real-world policy debates.

She  said:  “These doctors resilience and desire to help others was incredibly powerful and their fight to practice shows the impact you can have if you step outside your comfort zone, even against all the odds.”

Aaron Drovandi, Senior Lecturer in Medical Education Research at The University of Manchester, who was involved in the data and evaluation for REACHE said: “The team have achieved tremendous impact on international debate and national policy, with the work being  acknowledged by a broad range of stakeholders including the British Medical Association and World Health Organisation.”

Stephanie Harrison KC, Garden Court Chambers, said: “Our clients were highly qualified doctors who wished to provide their skills to NHS patients in need. One of our clients was able to take up a role that had remained unfilled for over a year. This is an important step but the full removal of restrictions still recommended. It is important that policy is guided by reason and compassion, recognising both the contribution individuals can make and the wider needs of society.”

Becky Hart, from Bhatt Murphy Solicitors, said: “We are glad the Secretary of State has agreed to amend her policy to expand the jobs those claiming asylum can work in… to include doctors, nurses, and other skilled occupations.”

Professor Nalin Thakkar, Vice-President (Social Responsibility), at The University of Manchester  said: “We are proud to have played a part in this success, which is a powerful illustration of how The University of Manchester values social responsibility and interdisciplinary collaboration.

“It also reflects our obligation, as a university, to act ethically, contribute positively to society, and prepare students not only academically but also as responsible global citizens. It is a concept that connects education with real-world impact, so that we do not exist in isolation but actively shape a better future.”

Image from left to right:
Front Row: Becky Hart Solicitor Bhatt Murphy; Isaac Ricca-Richardson KC Garden Court Chambers; Aisha Awan Senior Clinical Lecturer UoM, Director of REACHE 
Back row: REACHE Doctors;  Stephanie Harrison KC  Garden Court Chambers; Maeve Keaney - REACHE Founder; Maria-Ioana Dicu - UoM Yr 2 Computer Science Undergraduate, Faculty of Science and Engineering; Dorothy Anand - UoM Yr 2 Law Undergraduate, Faculty of Arts

Dr Benstead’s research investigates supply chain practices behind the global fashion industry, promoting sustainable practices, examining forced labour and modern slavery risks, and representation of workers’ rights throughout worldwide systems of supply.

Informed by her industry background and commitment to driving meaningful change across policy, industry and society, Dr Benstead aims to advance social justice in global fashion supply chains. She specialises in ethical and sustainable supply chain management, and critically examining the social inequalities embedded in global production systems.

Her work has shaped national and international policy, including contributions to UK government consultations and standards such as BS 25700 and ISO 37200. Most recently, she led a Leverhulme Trust–funded project on worker voice in Leicester’s garment industry.

The new members of the Young Academy have been selected for their track records of excellence in their respective fields, from global fashion supply chains and AI in drug discovery to paediatrics and infectious diseases.

This 2026 cohort includes seven members from the arts, humanities, and social sciences, increasing their representation to a third of total membership. A further 18 per cent of new members bring backgrounds in business, the public sector, and communications.

On Monday 23^rd and Tuesday 24^th March Amy attended the New Member’s Induction and All Member’s Meeting at the Royal Academy of Engineering and The Royal Society, their first opportunity to connect and exchange aspirations.

The new members took up their posts on Monday 23 March 2026, with membership running for five years.

Linda Oyama, representative of the UK Young Academy Executive Group said: “When we set out the UK Young Academy's 2023–2028 Strategic Plan, one of our core missions was to convene diverse voices to share ideas and improve decision-making, and to develop, connect, and mobilise early-career talent.”

Announced on Tuesday (24 March), the Russell Group’s 24 leading universities, including The University of Manchester, set out plans to train more than 181,000 students in subjects critical to health and care by 2030 – an increase of more than 15%. This includes doctors, dentists, nurses and midwives delivering frontline care, alongside engineers, social scientists and technology specialists whose expertise is increasingly essential to improving today’s healthcare services.

The University of Manchester already educates around 3,000 medical and dentistry students, and Russell Group universities in the North West collectively train over 17,000 people in the skills we need for a healthier future.  

The commitment will also support the growth of life sciences companies, helping to bring new treatments, technologies and high-skilled jobs to communities across the country.

While expanding training, universities will also work to remove barriers so that more students from disadvantaged backgrounds can access medical and health careers. This includes expanding initiatives, such as targeted gateway courses, summer schools and mentoring that make health and care careers more open to students from all backgrounds.

At The University of Manchester, the commitment builds on a long-standing focus on widening participation and supporting regional skills needs, particularly across Greater 91ֱ�� and the North West.

Professor Duncan Ivison, President and Vice-Chancellor of The University of Manchester, who is chairing the Russell Group working group behind the commitment, said: “One thing that distinguishes Russell Group universities – like The University of Manchester – is our unique combination of groundbreaking discovery research and our role in training the health workforce of the future.

“Our commitment is to training 181,000 graduates in health and care-related subjects by 2030, a 15% increase; increasing access for students from all backgrounds to join these vital professions; and supporting the growth of life sciences and innovation to help create high-skilled jobs and attract investment into communities.

“And we’re going to do it in partnership with the NHS and the patients, families, workers, industries and communities we serve. It’s about ensuring that the work of our universities translates into meaningful, real-world impact.

“There is more to do, but this represents an important step forward.”

The University of Manchester recently formed a new partnership with Wigan & Leigh College and the Greater 91ֱ�� Colleges network to place PhD researchers into Further Education classrooms, helping to strengthen teaching in priority subjects such as engineering, digital skills and STEM. The programme helps colleges with specialist expertise, while giving postgraduate researchers valuable teaching experience and building stronger links between further and higher education.

Other recent initiatives include hands-on pharmacy workshops and Healthcare Careers Pathway Days, offering students opportunities to meet professionals, visit campus and gain practical advice on applications.

The University also runs , such as Lancashire Access Medics and the , designed to support students from disadvantaged backgrounds into medicine.

While delivering on these commitments, Russell Group universities will for the first time convene a nationwide series of community engagement events.

The University of Manchester will host an in-person roundtable event bringing together partners from across the region to explore the future of the healthcare workforce. It will focus on how The University of Manchester can work with the health ecosystem in Greater 91ֱ�� to expand inclusive pathways into health careers and secure a strong and sustainable pipeline of talent for the NHS.

The rankings measure the quality and reputation of research and include measures on academic and employer reputation, citations performance and international collaboration.

The University remains in the top 40 globally in the broad subject rankings, with Engineering & Technology, Life Sciences & Medicine, and Social Sciences & Management all improving this year. Natural Sciences remained the same, while Arts & Humanities fell slightly. Life Sciences & Medicine achieved its highest ranking in the past seven years.

In individual subject rankings, the University was ranked in 46 subjects. Twenty subjects moved up in the rankings, 13 maintained their position and 13 declined.

Among the top performers, Geography moved into the global top 10, while Anatomy & Physiology rose into the top 25 worldwide.

Significant increases were also recorded in Medicine (up seven places to 26), Modern Languages (up seven places to 28), Physics (up 15 places to 34), Education (up 10 places to 35) and Dentistry (up to 48), reflecting the University’s continued strength across a diverse range of fields.

Professor Duncan Ivison, President and Vice-Chancellor, The University of Manchester said: “I am really pleased to see the strong progress across so many of our subjects in this year’s QS rankings. From Geography breaking into the top 10 to Life Sciences & Medicine achieving its highest rank in seven years, these results show how our colleagues across the University are excelling in teaching, research and innovation across a wide range of disciplines.

“We will continue to raise our standards, pushing to be at our best across everything we do, providing the best experience for our students and strengthening our position among the best universities in the world.”

Performance at the Detailed Subject Level 

• Four subjects ranked in the top 10 globally (up from three in 2025)
• 34 subjects ranked in the top 50 globally (up from 31 in 2025)
• 19 subjects ranked between 50-100 (up from 11 in 2025)
• A total of 45 subjects ranked in the top 100 worldwide (up from 44 in 2025) 

Top 10 Subjects 

Development Studies – ranked 5 (up from 11 in 2025)

Architecture – ranked 5 (same as 2025)

Geography – ranked 9 (up from 18)

Nursing – ranked 10 (same as 2025)

Subjects Ranked 11-25 

Petroleum engineering – ranked 12 (down from 10)

Materials science – ranked 17 (up from 21)

Engineering – chemical – ranked 17 (down from 16)

Pharmacy and pharmacology – ranked 18 (up from 25)

Sociology – ranked 20 (same as 2025)

Anthropology - ranked 20 (up from 21)

Accounting and Finance – ranked 21 (up from 23)

Chemistry – ranked 23 (down from 22)

English Language at Literature – ranked 22 (same as 2025)

Library and Information Management – ranked 23 (down from 20)

Anatomy and physiology – ranked 24 (up from 29)

Another 19 subjects are ranked between 26 and 50 and 19 between 50 and 100 globally, demonstrating a strong presence and broad academic excellence across subject areas.

The annual QS World University Rankings by Subject evaluate universities across 55 individual subjects and five broad subject areas, using indicators including academic reputation, employer reputation and research impact.

This year, QS analysed the reputation and research output of almost 6,277 institutions and 1,912 were ranked.

The University of Manchester is ranked 35th in the QS World University Rankings, 2025 (6th in the UK) and 46th in the Academic Ranking of World Universities, 2025.  It was also recently recognised with 10 subjects featured in the top 100 in the  for 2026.

“Thank you to the 57,000 young people who shared their views this year, and to the 161 schools who made it possible,” said Councillor Mark Roberts, Greater 91ֱ��’s portfolio lead for children and young people. “Over five years #BeeWell has now heard from more than 143,000 young people, making this the biggest exercise of its kind.

“In Greater 91ֱ��, we have committed to improving the wellbeing of young people across the city region, and it is through #BeeWell that we can track our progress. As this year’s results show, there is a need to continue strengthening relationships in schools to improve attendance, ensuring young people remain involved in the development of our Live Well approach, and working so that every young person has a clear line of sight to good jobs, through programmes like the MBacc and Beeline.

“We will continue to act on the views of young people across our city region, and be guided by our excellent Youth Steering Group, so that every young person in Greater 91ֱ�� can thrive.”

"This is just the start. It's encouraging to see wellbeing improving, but we are at the beginning of a long journey and we’re excited to see how things continue to improve,” said Daniel & Ayisha from the #BeeWell Youth Steering Group. “There are still worrying signs in the data, particularly in the inequalities we see. There are a lot of young people worried about these topics and a lot of work to be done. It's important young people are leading the next steps and actions following the results." 

The agreement to house the memorial at the University follows a commitment by Andy Burnham, Mayor of Greater 91ֱ��, to find a permanent and fitting home for it within the city-region. The memorial will now become part of the University’s collections, where it will be cared for as a place of remembrance, reflection and learning for generations to come.

Developed in collaboration with Inquiry participants, the memorial contains bottles with a message in each one written by someone affected by the scandal.

On display at the Infected Blood Inquiry until the publication of the Inquiry Report in May 2024, the memorial has been sited  in the . Its presence at the University will support research, teaching and public engagement, particularly in areas relating to patient safety, ethical practice in healthcare, trust, and health inequalities.

As a civic university rooted in 91ֱ��, the University is committed to working alongside communities to acknowledge difficult histories and to create spaces where reflection and learning can take place with care and respect. Through exhibitions, teaching programmes and public events including the annual Universally 91ֱ�� Festival, the memorial will remain accessible to the public, helping to ensure that the experiences of those affected continue to be heard and understood. 

By providing a permanent home for the Infected Blood Inquiry Memorial, the University hopes to honour those whose lives were changed forever, while supporting ongoing dialogue, understanding and learning that can help shape a more compassionate and responsible future in healthcare and public life.

Christine Burney, the widow of Peter Burney, who died of hepatitis following a blood transfusion said: “I lost my husband Peter Burney in 2019 to liver cancer, after being given hepatitis C following a blood transfusion. The inquiry memorial holds deep personal significance. As I live on the outskirts of Manchester I have visited it numerous of times since its arrival on the university grounds, finding solace in its presence.

It serves as a vital, permanent reminder of this tragedy for the medical professionals of tomorrow. My hope is that by including this history in their curriculum we ensure that the lessons of the past directly inform the care and ethics of the future.”

Sir Brian Langstaff, Chair of the Infected Blood Inquiry, said: “We must never forget the devastating effects of what happened. Foremost among them is the anguish, suffering and profound loss, so eloquently highlighted by the messages carefully placed in this Memorial by people infected and affected.  I wish to thank the University of Manchester for providing a permanent home for the Memorial. It stands now, and for the future, as a testament to all of those who fought so long to be heard.  The infected blood disaster was not an accident and its like must never happen again.” 

Andy Burnham, Mayor of Greater 91ֱ��, said: "This memorial is a powerful way to honour those thousands of people and their family members who suffered so much and those whose lives continue to be blighted by the infected blood scandal.  I hope this memorial provides some closure, and a place for reflection for all people fighting injustice.

“I pay tribute to the campaigners like Fred and Eleanor Bates from Wythenshawe who never gave in and helped me understand the scale of the injustice. I am proud that the memorial will be based here, in the centre of Manchester, and I know they would be too.”

Professor Stephanie Snow, Professor of Health, History and Policy and Academic Lead for Public Engagement who is based at The University’s  Centre for the History of Science, Technology and Medicine said: “Our stewardship will honour the Inquiry’s intention that the Memorial will be a permanent symbol of the human suffering and loss caused by the contaminated blood scandal.

“Many thousands of NHS patients were infected after being given contaminated blood in what has been called the biggest treatment disaster in the history of the NHS.

“According to the inquiry, the victims had been failed "not once, but repeatedly", since 1948, the date when the risk of viral infections in blood products originated. This memorial is a fitting tribute and a powerful reminder of their story. We are honoured it is to become part of the University’s collections.

John McAuliffe, Associate Vice President (Cultural Portfolio) at The University of Manchester and Director of was also part of the team who helped to bring the monument to 91ֱ��.

He said: “Our collections inspire and nurture world-class research, teaching and learning and this memorial will be of huge interest to writers, historians, social scientists, clinicians and scientists,  and others connected to the Centre for the History of Science, Technology and Medicine, and to the University’s research platforms, Creative 91ֱ�� and Healthier Futures, which support interdisciplinary research, as well as to colleagues and students attached to the Justice Hub, the Centre for New Writing and the Granada Centre for Visual Anthropology.

Professor Nalin Thakkar, Vice-President for Social Responsibility at The University of Manchester said: “As a civic university, we believe it is important to remember difficult histories with honesty, compassion and respect. The Memory Bank Memorial gives powerful voice to those affected by the contaminated blood scandal and stands as a reminder of the human impact behind it. 

“It is a privilege for the University to become its custodian, and we hope it will support reflection, learning and dialogue for generations to come, reflecting our commitment to social responsibility and to serving our communities in 91ֱ�� and beyond.”

• Image from left to right: Sir Brian Langstaff, Andy Burnham, Stephanie Snow, Clair Walton, Nalin Thakkar

Poorer communities often face additional difficulties to accessing consistent, proactive and clearly defined dementia support within general practice.

Based on 20 in‑depth interviews with people with dementia and their carers, the researchers highlight how socioeconomic disadvantage  adds additional  complexity to their healthcare.

Funded by the National Institute for Health and Care Research (NIHR ) School for Primary Care Research, the study is published in the .

Participants were recruited from areas ranked in the lowest two quintiles of the ensuring that voices often absent from dementia research were highlighted.

The researchers analysed the interviews using reflexive thematic analysis, a qualitative research method used to identify, analyse, and interpret patterns of meaning.

It revealed four interconnected themes that shaped participants’ experiences:

• Proactive continuity of care is essential to helping people with dementia retain a sense of identity as the condition advances.
• Formal support often falls away just as care needs escalate, leaving families feeling abandoned at the most critical stages.
• Widespread difficulty navigating what respondents see as a fragmented and often bewildering primary care system.
• Uncertainty across general practice about who is responsible for ongoing dementia support, with many patients and carers unclear about where the condition sits within routine care.

While views varied, some participants felt local resources and individual social networks influenced the quality of care they received.

The findings suggest that clearer communication, proactive follow‑up and more consistent relationships with primary care professionals could significantly improve the experiences of people with dementia.

The study also emphasises the need for a clearer definition of primary care’s role in dementia management, particularly as policy discussions increasingly point toward primary care‑led post‑diagnostic support.

Lead researcher Dr from The University of Manchester said: “It was a real privilege to interview the people with dementia and the carers for this study, and I’m very grateful to them all.

“Our work shows that people with dementia in disadvantaged areas are navigating a system that often feels fragmented, reactive and unclear, at a time when stability and continuity matter most.”

“By strengthening proactive contact and clarifying who is responsible for dementia care, primary care services can make a profound difference to patients and families.

“Addressing these gaps is essential to ensuring equitable, person‑centred dementia care across the UK.”

Co-author , director of the NIHR Greater 91ֱ�� PSRC and professor at The University of Manchester, added: “The themes we identified are an important insight into how people with dementia feel about the healthcare they receive from their primary care teams.

“Understanding this is an important step to improving the post-diagnostic healthcare we offer for people with dementia in the community.”

• The paper Experiences of primary care for people with 2 dementia from socio-economically 3 disadvantaged areas: a qualitative study, published in the British Journal of General Practice is available DOI: https://doi.org/10.3399/BJGP.2025.0407

Delivered collaboratively by the Universities of Manchester, Bristol and Liverpool, the new PhD Programme will train 40 of the UK’s most promising scientists to move beyond disciplinary boundaries and adopt integrated approaches to heart–brain health.  Together, they will uncover the biological and societal drivers that link heart and brain diseases, develop new tools for early detection, create predictive digital models for personalised care, and design therapies that target shared pathways across both organ systems. This integrated approach reflects the growing need for preventative, system-level solutions as populations age and multimorbidity rises.

 Recognising the need for integrative research linking heart and brain diseases, the programme is centred on the principles of multidisciplinary. Students will work on ambitious cross-disciplinary projects spanning discovery bioscience, engineering, data science, imaging, epidemiology and behavioural science. Bringing these different perspectives together will enable new insights into complex disease processes and help drive innovative solutions to some of the biggest challenges in cardiovascular and neurological health.

Cohort-based training across all three universities, alongside strong industry partnerships and access to world-leading infrastructure, will provide students with a rich and collaborative research environment. Together, these opportunities will equip them with the skills, networks and experience needed to become the future leaders driving innovation in cardiovascular and neurological research, with real impact for patients and health systems alike.

The programme application was led by Dr Gina Galli (University of Manchester), Professor Deirdre Lane (University of Liverpool) and Professor Alastair Poole (University of Bristol), who will be Directors of the new programme. For 91ֱ��, this sees a continuation of our sustained BHF-funded PhD programme that has been running successfully since 2009, training present and future generations of cardiovascular researchers.

Professor Ashley Blom, Vice President and Dean of Biology, Medicine and Health at The University of Manchester said: “We are delighted to be part of this national training programme which looks at  the links between heart and brain diseases, an important yet under-researched area of  cardiovascular medicine.”

Analysis was carried out by the University of Manchester’s Dr Luke Munford, using Understanding Society data, a nationally representative survey of over 20,000 households across the UK.

The analysis reveals that young people living in the UK’s lowest income households are around three and a half times more likely to be out of work and education than those from the highest (25% vs 7%). Similarly, those whose parents had no formal qualifications were around two and a half times more likely to be NEET than those whose parents had a degree level qualification (24% vs. 9%)

The data also shows entrenched regional disparities. The North East has seen persistently high rates over the last 15 years and right now, the North East (18%) and West Midlands (17%) have NEET rates almost double that of the South East (10%). This reflects wider trends in employment rates and educational performance.

One trend that has emerged however, is the finding that men are now more likely to be NEET than women. 20% of millennial women were likely to be NEET in 2009-10, compared with 17% of millennial men but now, Gen Z men (15%) are now more likely to be NEET than Gen Z women (12%) in 2023-24. This could indicate two things: that fewer women are out of the workforce due to caring responsibilities, and that changes to the types of jobs available - such as manufacturing and manual labour - are disproportionately affecting men.

On top of this, the proportion of NEET young people with a likely mental health condition has doubled over the last 15 years. Of those 16-24 year olds who were NEET, 30% had a likely mental health condition in 2009-10, increasing to 60% in 2023-24. Better diagnosis and awareness plays a big role in this trend, which is positive, but must be met with better support.

Work and education are key building blocks of health. The government’s announcements this week of the Youth Jobs Grant, apprenticeships incentive and the expansion of the Jobs Guarantee are all welcome measures to give young people the best chance possible to get a foothold in the workplace. But as this data shows, these initiatives must support those with the greatest need, so that communities don’t continue to be left behind.*

Awaiting former health secretary, Alan Milburn’s imminent investigation into the ‘lost generation’ of young people not earning or learning, Health Equals and its members and supporters are calling for the government to invest in community-based support to get people back into employment, and work with employers and education providers to prioritise prevention to stop people from becoming NEET in the first place.

Paul McDonald, Chief Campaigns Officer at Health Equals, said: “This data tells a story of deep-rooted generational inequalities in the UK, creating a vicious cycle where some young people are being forgotten.

“The right job or training can do so much more than simply pay the bills or help you learn a new skill. It can bring financial stability, a sense of purpose and achievement. When we’re in good, stable employment, education or training, we’re more likely to stay mentally and physically well.

“Labour’s growth agenda hinges on the country being in good health, and crucially, ensuring communities aren’t left behind. That’s why health needs to become a key pillar in every decision this government makes. A cross-government health inequalities strategy that prioritises prevention, sets ambitious targets and makes better health a shared goal for every part of government will set us on the right course to make health equal in the UK.” 

Dr Luke Munford, Health Economist at the University of Manchester and academic co-director of Health Equity North said: "Our analysis shows a worrying reversal in progress. After years of decline, the proportion of young people who are NEET has risen again. Even more striking is the sharp increase in mental ill-health among NEET young people: double the rate seen among Millennials.

“The evidence is clear: government must offer a package of support to meet mental health needs, expand high-quality training and apprenticeships, and target resources to regions and groups facing the greatest disadvantage. Without decisive action, we risk embedding inequalities that will shape outcomes for decades to come." 

Jordan Cummins, UK Competitiveness Director at CBI, a Health Equals member, and Chair of Health Sciences University said: 'Business fully understands the centrality of their role in working with government to address the rising number of young people who're falling out of employment, education and training, and are acutely aware of the health drivers within this. Though without tackling the rising cost of business, alongside the cost of living, their ability to create jobs and training will remain limited. Collective approaches designed to unlock investment and intervention are essential to help government and industry play their equally important roles.'”

Becci Newton, Director of Public Policy Research at the Institute for Employment Studies, a Health Equals member, said: “This data shows a stark divide in young people’s life chances. Those from the poorest households are three and a half times more likely to be NEET than those from the richest, and the number of NEET young people with a likely mental health condition has doubled to 60% in just 15 years. 

“We need urgent government action: earlier mental health support, better access to quality training and apprenticeships, and locally tailored help to get young people into good work. Without it, we risk writing off a generation.”  

Health Equals and its members are calling for a cross-government Health Inequalities Strategy to make health equal across the UK To be part of the solution, visit:

Let’s #MakeHealthEqual

Led by the University’s Science & Engineering Education Research and Innovation Hub (SEERIH), the Great Science Share for Schools encourages pupils aged 5–14 to ask, investigate and share scientific questions that matter to them. By placing curiosity at the centre of learning, it supports the development of scientific literacy, creativity and confidence from an early age empowering children to see themselves as active participants in science.

Its reach and inclusivity are among its greatest strengths and Great Science Share for Schools continues to build global momentum. In 2025 alone, more than 845,000 young people from over 4300 schools in 52 countries took part, with around 50% of participants located in areas of high socio-economic deprivation. This reflects the initiative’s position as a worldwide leader in child-centred science engagement and its strong commitment to widening access and ensuring science is accessible to all, regardless of background.

The University continues to play a central role in this growth. In 2025, during the programme’s 10^thanniversary year, we welcomed over 35 schools from across Greater 91ֱ�� onto campus for hands‑on science activities that connected children directly with our colleagues, facilities and scientific community.

With the campaign having received patronage of the UK National Commission for UNESCO in 2024, 2025 and 2026, focus is now on the global growth of GSSfS. With its inclusive, non-competitive and collaborative approach, the format is easily translatable to 5–14-year-olds across the globe to ask a scientific question, investigating it and sharing it in various means of communication.

Great Science Share for Schools provides opportunities for university academics and research to feature in the campaign through the resources produced each year. The campaign has also worked closely with 91ֱ�� Museum staff and the University’s Creative 91ֱ��.

The impact of Great Science Share for Schools over the past decade was recently recognised in a feature in the , which highlighted the programme’s 91ֱ�� roots, its global influence and its success in empowering hundreds of thousands of children to explore the world around them. By nurturing curiosity, confidence and a lifelong love of science, the initiative continues to demonstrate the power of meaningful engagement with young learners.

• Further information can be found here on the .
• Please contact us if you are interested in collaborating on the campaign.
• See the full article in the 

According to The University of Manchester led on mice, published in the American Heart Association Stroke journal today (insert date) and funded by the Medical Research Council, the timing of anakinra must be adjusted to avoid reducing the benefits of the clot‑busting therapy known as tissue plasminogen activator(tPA).

Stroke is the second leading cause of death and disability worldwide; experts estimate the number of people affected could rise by more than 80% over the next 25 years.

But despite decades of research and thousands of experimental drugs, the only approved medicines for treating the most common type of stroke — ischemic stroke — are clot‑busting drugs known as plasminogen activators, like tPA.

Though tPA can be lifesaving for acute ischemic stroke, about 2–6% of treated patients develop potentially fatal brain bleeding, according to the ECASS III trial of the early 2000s.

Though it must be given within 4.5 hours of symptom onset, many patients arrive too late or don’t know when symptoms started.

Scientists now know that inflammation plays a major role in worsening brain injury after a stroke, mostly driven by a molecule called interleukin‑1 (IL‑1).

Anakinra  - an interleukin‑1 receptor antagonist (IL‑1Ra) -  blocks IL‑1 and has shown promise in reducing inflammation in both laboratory and early clinical studies of stroke.

However, a  phase II clinical trial known as SCIL‑STROKE based at The Northern care Alliance NHS foundation Trust found that IL‑1Ra did not improve patient recovery overall.

“The findings of SCIL‑STROKE raise questions about whether the drug might interact negatively with standard clot‑busting treatment, “ said lead author , based at the University of Manchester.

Because nearly three‑quarters of patients in the SCIL‑STROKE trial received the clot‑busting drug tPA before IL‑1Ra, the researchers set out to investigate whether the two treatments might negatively interact  with each other.

They re‑examined data from the SCIL-STROKE trial and discovered that patients who received tPA before IL‑1Ra had significantly lower levels of IL‑1Ra in their blood, suggesting the drug was being broken down.

Laboratory research confirmed that IL‑1Ra can be cut apart by plasmin, an enzyme produced during tPA treatment, meaning the anti‑inflammatory drug may be degraded before it can work.

Researchers then tested the interaction in a mouse model of stroke, using dosing schedules that matched those used in the clinical trial.

When IL‑1Ra was given after tPA, no harmful interaction was seen, and the protective effects of tPA were preserved.

However, when IL‑1Ra was given at the same time as tPA — during the clot‑busting process — the benefits of tPA were dramatically reduced, with brain damage shrinking by only 15% compared to 68% with tPA alone.

The mice receiving both drugs together also showed poorer blood flow in the brain, more inflammatory immune cells entering damaged tissue, and higher levels of harmful structures called neutrophil extracellular traps. This indicates that the drug interaction is also detrimental to the anti-inflammatory effect of IL-1Ra.

Dr Mosneag added: “Our findings suggest that IL‑1Ra can interfere with tPA’s ability to dissolve clots when the two drugs are present in the bloodstream at the same time.

“The results also help explain why IL‑1Ra levels were lower in patients who received tPA first, as plasmin generated during clot‑busting appears to break down IL‑1Ra.

”However, the  effect of tPA on IL-RA -  the opposite order -  isn’t necessarily a problem  as IL-1RA was still active in reducing IL-6 in the SCIL-STROKE study, but this needs further evaluation.”

Co-author Professor from The University of Manchester said: “This study  shows that timing is very likely to be a critical factor in the efficacy of  IL‑1Ra, which  will be beneficial if given after tPA rather than alongside it.

“We also need to test whether similar interactions occur with other clot‑busting drugs such as tenecteplase, which may be less likely to break down IL‑1Ra due to its greater specificity.”

Co-author from the University of Manchester said: “This study has important implications for further development of IL-1Ra as a treatment for ischaemic stroke, where there remains a focus on maximising delivery of thrombolysis drugs to eligible patients as quickly as possible in clinical care.  Future studies will need to investigate the timing and effectiveness of IL-1Ra treatment after receiving tPA.”

• The paper Timing-dependent cleavage of Interleukin-1 receptor antagonist by alteplase impairs neuroprotection in ischemic stroke is available

“Understanding these changes is important because social media rules now influence how societies talk about politics, share information, and handle disagreements, which has big effects on democracy and public debate.”

DOI:

DOI:  

Working Well: Roots to Dental Jointly led by University of Manchester, University Dental Hospital of Manchester, part of Manchester University NHS Foundation Trust, and Greater 91ֱ�� Combined Authority (GMCA). The scheme has already shown how addressing oral health can make a real difference to people’s lives, improving residents’ confidence and readiness for work while supporting the training of the next generation of dentists.

One participant said: “Previously I struggled with pain when eating and sensitivity all the time. I could not drink without a straw, and this makes people look funny at you. Now I have had two root canals on my front teeth I can bite better and eat better, and it’s not sore. I feel more confident to smile as my teeth are a much better colour. I can’t wait to have the rest of them done... I think it will improve my employment prospects by looking better and having less pain.”

This success comes against a wider backdrop of unemployment linked to health and disability in Greater 91ֱ��, with oral health emerging as a significant but often hidden barrier to accessing and sustaining good jobs. Working Well: Roots to Dental is a leading example of how to integrate oral health and employment support as well as giving opportunities to dental students to make a difference to local communities. It connects directly to Greater 91ֱ��’s ambition to remove barriers to good jobs by providing everyday, neighbourhood‑based support that links health, skills and opportunity, so residents can thrive in work and life.

Following a successful pilot supporting over 200 residents, the scheme was recognised with an Employment Related Services Association (ERSA) Employability Award for Adding Social Value, won in partnership with employment support provider Ingeus. It now plans to widen access to even more Greater 91ֱ�� residents through the Working Well programme and other selected referral pathways, so that more people can benefit from integrated dental treatment and employment support.

Cllr Eamonn O’Brien, Greater 91ֱ�� lead for Technical Education and Skills, said:  

“Roots to Dental shows what’s possible when we join up health, skills and employment support in a way that works for everyone. Residents are getting the treatment and confidence they need to move closer to work, while dental students gain vital, real‑world experience that prepares them for their future careers.”

Sarah-Jade Akintomide, undergraduate dental student said:

“Through Roots to Dental, I am learning to deliver high-quality treatment to help people smile again. It's about more than just teeth; it's about restoring people's confidence and improving their quality of life.”

Professor Allan Pacey, Deputy Dean and Deputy Vice President of the Faculty of Biology Medicine and Health said:

“Social Responsibility is a core goal at The University of Manchester and so I am delighted that our students are making a real difference in communities where change is so desperately needed.”

• Working Well is a family of services that support people experiencing or at risk of long-term unemployment due to poor health or complex needs.
• To date, over 92,000 residents in Greater 91ֱ�� have been supported.
• Working Well: Roots to Dental has recognised unmet need in relation to oral health and employment. Many participants were living in dental pain and felt embarrassed about their teeth, impacting on their ability to move into work.
• Data from a cohort of 4,469 participants in a related Work and Health programme showed:

o   10% had pain or problems in their mouth

o   A further 10% felt embarrassed about speaking and smiling due to dental issues

o   40% of participants had no access to a regular dentist

• Residents or key workers supporting Working Well services can find out more on the Greater 91ֱ�� Combined Authority website:

The result is the first particle discovery made using the upgraded LHCb detector, a major international project involving more than 1,000 scientists across 20 countries. The UK made the largest national contribution to the upgrade, with significant leadership from 91ֱ��.

The newly observed Ξ_cc⁺ is a heavier relative of the proton, which was famously discovered in 91ֱ�� by Ernest Rutherford and colleagues in 1917-1919. The proton contains two up quarks and a down quark. The new discovery replaces the up quarks with their heavier relatives the charm quarks. It also extends a legacy begun in the 1950s, when 91ֱ�� physicists were the first to identify a member of the Ξ (Xi) particle family.

Professor Chris Parkes, head of the University’s Department of Physics and Astronomy, led the international collaboration during the installation and first operation of the LHCb Upgrade detector. He also led the UK contribution to the project for over a decade, from approval through to delivery.

The 91ֱ�� LHCb group designed and built key components of the upgraded tracking system, the silicon pixel detector modules assembled in the University’s Schuster Building. These detectors are central to precisely reconstructing the particle decays in which the Ξ_cc⁺ signal was observed.

said: “Rutherford’s gold‑foil experiment in a 91ֱ�� basement transformed our understanding of matter, and today’s discovery builds on that legacy using state‑of‑the‑art technology at CERN. Both milestones demonstrate just how far curiosity driven research can take us. This discovery showcases the extraordinary capability of the upgraded LHCb detector and the strength of UK and 91ֱ�� contributions to the experiment.”

, from The University of Manchester, who led the silicon detector module production, added: “The detector is a form of ‘camera’ that images the particles produced at the LHC and takes photographs 40 million times per second. It utilises a custom designed silicon chip that also has a variant for use in medical imaging applications.”

The Ξ_cc⁺ particle was identified through its decay into three lighter particles (Λ_c⁺ K⁻ π⁺), recorded in proton‑proton collisions at the LHC in 2024, the first year of full operation of the LHCb Upgrade experiment. A clear peak of around 915 events was observed at a mass of 3619.97 MeV/c², consistent with expectations based on a previously discovered partner particle, the Ξ_cc⁺⁺.

This observation resolves a question that had remained open for more than two decades since an unconfirmed claim of the observation of this particle was made. The particle has now been discovered by LHCb at a mass incompatible with this earlier claim and a mass that is compatible with the theoretical expectations based on the partner particle.

In the next phase of the LHC programme, The University of Manchester is playing a leading role in LHCb Upgrade 2, which is planned to take advantage of the High-Luminosity LHC accelerator. 

Professor Parkes added: "This discovery highlights the exciting scientific opportunities ahead as we prepare for the next generation of upgrades. Continued UK involvement in LHCb Upgrade 2 will be key to ensuring the UK remains at the forefront of particle physics."

Details of the Ξ_cc⁺ discovery are presented at the Rencontres de Moriond Electroweak conference.

She added: “Separate from the UKCHA, the University of Manchester has research partnerships with Tsinghua University, Peking University, Fudan University, Wuhan University and Chinese University of Hong Kong. Becoming the lead UK-based Coordinating Team reflects our ongoing commitment to supporting high quality, impactful research between world-leading Humanities academics.” 

Established in 2016, The UKCHA’s aim is to intensify international cooperation in Humanities. This includes joint work on research and publication, staff and research exchanges, and connections with specialist arts and cultural institutions.   

The announcement has been made as part of a high-level delegation from The University of Manchester to Beijing, Shanghai and Hong Kong. Led by Professor Duncan Ivison, President and Vice-Chancellor and including a delegation of academic and university staff, the visit is connecting with alumni, donors, partners and universities. 

The visits are in conjunction with the University of Manchester China Centre and the East Asia Centre, based in Hong Kong and will also include a graduation ceremony in Shanghai and launch events for the University’s fundraising and volunteering campaign, Challenge Accepted. 

This pioneering study, led by scientists at the University of Manchester and involving teams in Denmark, has been published in

In what is considered a major breakthrough in the battle against brain cancer, scientists have found early evidence that a pair of proteins in the blood may help identify glioblastoma with high accuracy and provide insights into how the disease responds to treatment.

Glioblastoma is notorious for late diagnosis, rapid progression, resistance to treatment and extreme biological complexity. At present, diagnosis and follow-up rely largely on MRI scans and invasive surgical biopsies, which can miss early changes and cannot be repeated frequently. As a result, clinicians often struggle to determine in real time whether a treatment is working or whether the tumour is beginning to return.

The new research shows that two blood-borne proteins – coagulation factor IX (F9) and cartilage oligomeric matrix protein (COMP) – form a powerful “dual-marker” signature that distinguishes patients with glioblastoma from healthy individuals with high accuracy (more than 90%). In samples taken from patients during surgery, radiotherapy and chemotherapy, the markers showed dynamic changes, reflecting treatment response and disease progression.

Professor, The Brain Tumour Charity chair of Translational Neuro-Oncology at The University of Manchester, who led the study, said: “Glioblastoma is one of the most devastating cancers we face. Late detection is among the contributing factors to poor outcomes and a source of anxiety our patients face leading up to their diagnosis. The lack of reliable tests has been a major barrier to earlier diagnosis and treatment response monitoring. What is remarkable about our findings is that, despite these tumours being very different in genetic make-up, and constantly evolving, the signal in the blood is stable, robust and highly informative. We hope that once validated, this simple blood test may pave the way for earlier diagnosis and more precise monitoring of patients during and after therapy.

 “Our dual-marker blood test achieved diagnostic accuracy greater than 90 percent and continued to perform just as well when the disease returned. This opens the door to a future where we can follow the tumour’s behaviour through a simple blood sample, complement brain scans, and potentially recognise when the treatment isn’t working and the cancer returns much earlier than is currently possible. We still have a long way to go before we would see this used in clinic, but it’s a very promising and exciting development in neuro-oncology research.”

Dr Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, said: “We are immensely proud to support Petra’s role as The Brain Tumour Charity’s Chair of Translational Neuro-Oncology through a grant worth £1.35 million. Early and accurate diagnosis is absolutely critical for people with brain tumours, yet current tools are limited and often invasive. This research therefore marks a significant step towards a simple blood test that could help clinicians detect glioblastoma and monitor how patients are responding to treatment in real time.”

Professor Hamerlik, who is also the brain tumour lead for concluded: “While validation of this finding is ongoing with the generous contribution of UK patients who kindly donated their blood for this research, our results strongly support the development of a clinically accessible blood test for glioblastoma. Ultimately, this could help doctors make more informed treatment decisions, reduce the need for repeated invasive procedures, and, most importantly, give patients and families clearer, earlier answers.”

The study was co-funded by The Brain Tumour Charity and conducted at The University of Manchester and the 91ֱ�� Cancer Research Centre (MCRC), reinforcing 91ֱ��’s leading role in translational neuro-oncology research. The Danish Cancer Society and NovoNordisk Foundation in Denmark also part-funded this study.

• The paper Non-Invasive Detection and Monitoring of Glioblastoma Subtypes via Dual-Marker Plasma Proteomics DOI
• Philanthropic support has been central to enabling this research. The University is proud to partner with the Brain Tumour Charity and a number of individual donors who support Petra and her team's work. Find out more about how supporting 91ֱ�� drives impact across our research here: Challenge Accepted

SATURN-2 (Skills and Training Underpinning a Renaissance in Nuclear) builds on the success of the original , doubling its size and introducing expanded training pathways across the entire nuclear fuel cycle. The programme will recruit around 50 PhD/EngD students per year for the next four years, delivering just under half of the 500 high skill nuclear doctoral graduates the UK is estimated to need by 2030.

The programme brings together seven universities: The University of Manchester (lead), The University of Liverpool, Lancaster University, The University of Strathclyde, The University of Sheffield, The University of Leeds, and Bangor University. These universities represent more than 70% of the UK’s nuclear academic community and deliver expertise across the entire nuclear fuel cycle.

Backed by £8 million of industrial co‑investment and £4 million from university partners, SATURN-2 represents one of the most significant UK investments in advanced nuclear skills in over a decade.

The programme also maintains a strong regional base across the North West, North Wales and Scotland, home to the UK’s most concentrated cluster of nuclear industry, research facilities and workforce.

, SATURN CDT Director from The University of Manchester said: “This Doctoral Focal Award reflects the success of the original SATURN Centre for Doctoral Training and its important role in supporting the government’s ambitions for Nuclear. Building on that foundation, SATURN-2 will expand the programme significantly, while continuing to deliver world-leading training for the next generation of specialists the UK needs in this sector. We are proud to lead this collaboration with outstanding partners across the UK.”

Meeting critical UK skills needs

The UK Government’s Strategic Defence Review and National Nuclear Strategic Plan for Skills highlight an urgent shortage of high skill nuclear scientists and engineers, with an estimated 120,000 workers needed by the 2030s, including a rapidly depleting cohort of subject matter experts.

SATURN-2 directly addresses this challenge by training specialists across:

• Nuclear fuel manufacture and performance
• Reactor science, engineering and operations
• Decommissioning and waste management
• Fusion‑fission interfaces
• Digital engineering, robotics and AI in nuclear contexts

Students will benefit from an enriched training programme including a three‑month residential bootcamp, specialist modules across the partner institutions, international experiences at leading laboratories, and secondments into industry, national labs and government agencies.

Professor Charlotte Deane, Executive Chair at UKRI’s Engineering and Physical Sciences Research Council said: “The UK's nuclear sector is central to our national security, clean energy ambitions and economic future. Meeting those challenges demands a new generation of researchers and innovators with the technical expertise to make a real difference. 

“UKRI doctoral focal awards are a proven way to develop that talent. They bring together academic excellence, industry partnerships and cohort-based learning to give doctoral students the skills and experience to make an immediate impact in the nuclear workforce.  

“These new nuclear focal awards, developed in partnership with government, will continue building the research base that the UK's national security and clean energy future depends on.” 

A proven pipeline into the nuclear workforce

Over 15 years of predecessor CDTs, Nuclear First, Next Generation Nuclear, GREEN and SATURN, the consortium has trained more than 300 doctoral researchers, with exceptionally strong career outcomes.

High‑level destination data shows that:

• 75% of graduates now work directly in the nuclear industry
• 18% progressed into education or academia
• 5% are employed in nuclear‑relevant government roles

These figures demonstrate the CDT’s sustained role as the UK’s most effective route for producing nuclear subject matter experts.

Exceptional industrial engagement

SATURN-2 is supported by 22 industry partners spanning the civil, defence and advanced nuclear sectors, including Rolls Royce, BAE Systems, Sellafield Ltd, the Nuclear Decommissioning Authority, AWE, EDF, UK NNL, Urenco, Framatome, AtkinsRéalis and Rapiscan.

Industrial partners have committed:

• 48 co‑funded studentships
• ~£4 million of in‑kind support (supervision, placements, facilities, equipment, training)

Industry demand for SATURN trained researchers continues to rise, demonstrating trust in the consortium’s ability to deliver highly employable graduates ready for the most complex national nuclear challenges.

Supporting additional national doctoral centres

In addition to leading SATURN‑2, The University of Manchester is also a supporting partner in several of the newly funded Centres for Doctoral Training announced alongside SATURN‑2, including:

• RAPTOR (Radiation Protection, Nuclear Safety and Environmental Sustainability), led by the University of Liverpool
• DRIVERS (Developing Researchers with an Interdisciplinary Vision for Engineering Reactor Systems), led by Imperial College London
• PANDA (Programme for Accelerating Nuclear Development and Applications), led by Bangor University

The work reflects the University’s wider role in strengthening the UK’s national nuclear skills pipeline.

Faye brings extensive experience in the Cambridge innovation cluster to the role, having worked across communications consultancy, innovation and economic development over the course of her career.

She founded and directed cofinitive – a communication consultancy at the forefront of innovation – for a decade before selling and exiting the business at the end of 2025.

Faye is currently Chair of the Cambridgeshire Chamber of Commerce and has previously served as Business Board Member for the Cambridgeshire & Peterborough Combined Authority and as a Board Member and key contributor in other organisations involved in technology innovation and good growth.

Faye said of her appointment: “I’m thrilled to be leading this partnership at a time when collaboration across the UK’s innovation ecosystems has never been more important.

“Cambridge and Greater 91ֱ�� are two of the UK’s most dynamic innovation ecosystems and by working together we can deliver far greater impact than either could alone. I’m excited to work with partners across both cities to move quickly and define a model for collaboration that could be replicated across the UK.”

Faye’s appointment follows on from the launch of the partnership last year and the inaugural board meetings held in 91ֱ�� in February 2026.

Driven by the cities’ respective universities and their innovation ecosystem organisations  and , the partnership aims to boost UK economic growth and advance inclusive innovation, while supporting the delivery of industrial strategy and local growth plans. 

Professor Duncan Ivison, President & Vice-Chancellor of The University of Manchester, said: “Innovation is at the heart of our 91ֱ�� 2035 strategy and our sector-first collaboration with Cambridge plays a key role in this. We are working together and using our respective strengths to create a thriving cross-city innovation network, helping to grow investment and deliver inclusive growth. 

“I am so pleased to welcome Faye at such an exciting time for the partnership, and she joins us following an extensive career within the Cambridge innovation cluster. The partnership is a fantastic example of how universities can use their resources to contribute significantly to the economy, and we are all ready to work with Faye to drive it forward.” 

Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge commented: “I am delighted to welcome Faye Holland as the new Director of the Cambridge x 91ֱ�� Partnership. Faye brings an exceptional understanding of the Cambridge innovation ecosystem, alongside a proven experience of convening organisations, championing talent, and strengthening regional collaboration. Her appointment marks an exciting next chapter for this strategic partnership between two great cities and universities.”

As Director, Faye will spend time in Cambridge and 91ֱ�� and will be integral to both the Unit M and Innovate Cambridge leadership teams, and she will drive the partnership forward as it strives to pioneer a new model of place-to-place collaboration.

Professor John Holden, Vice-President for Civic Engagement and Innovation at The University of Manchester, said: “The Cambridge x 91ֱ�� Partnership shows how universities can exchange knowledge, talent and assets and bring together their wider ecosystems to supercharge innovation and growth. Under Faye’s expert direction, this partnership will produce real-world impact and provide an example for other cities to follow.”

Dr Kathryn Chapman, Executive Director, Innovate Cambridge commented: “Faye has an outstanding track record of working with innovators and turning ambition into impact. As we move into the next phase of delivery, with strong backing from government, academia and business, her leadership will play a key role in strengthening research networks, supporting the growth of scale-ups and attracting further private investment.”

The partnership is a major focus for both cities, backed by each’s respective combined authorities, and has secured £4.8 million from UKRI Research England over the next three years and is bolstered by further investment from both universities.

Dr Simon Hepworth, Director of Knowledge Exchange at Research England, said: “Universities are driving the evolution of innovation ecosystems through bold new models of collaboration. The appointment of Faye Holland will help drive the Cambridge x 91ֱ�� innovation partnership forward and deliver successful outcomes for the country – to maximise opportunities for place-based innovation, economic growth, and as an exemplar for the wider HE system."

The partnership is connected at every level: University to University, innovation ecosystem to ecosystem, council to council, Combined Authority to Combined Authority and business to business. This multi-layered connectivity allows ideas, talent, investment and opportunity to flow between places and organisations.   

To find out more about the partnership, visit:   

DOI:  

The research, published in is part of the Stroke IMPaCT study (Stroke – Immune Mediated Pathways and Cognitive Trajectory), a network of European and North American researchers who are working to discover how inflammation and immune responses contribute to post-stroke cognitive decline.

The team followed patients treated for an ischaemic stroke at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust. They measured levels of a protein called interleukin-6 (IL-6) in the days after stroke and again at both 6-9 and 18-21months. Participants also completed detailed tests of memory and thinking.

Interleukin-6 levels increased soon after stroke and, in most people, fell back to typical levels within 6-9 months. But in some patients, levels stayed high or rose again. These individuals were about eight times more likely to develop difficulties with thinking ability.

The researchers also saw differences between smokers and non-smokers. Smokers showed a different pattern of IL-6 change after stroke, with signs of longer-lasting inflammation. This ongoing inflammation was more strongly linked to problems with thinking and memory.

Lead author an MBPhD researcher at The University of Manchester, said: “Inflammation after stroke doesn't just happen once and disappear. By tracking this protein over time, we may be able to identify patients at greater risk of cognitive problems and eventually tailor support or treatments to them.”

Professor Craig Smith, Professor of Stroke Medicine at The University of Manchester and Consultant at Salford Royal, said: “Our findings suggest it's not just the initial spike in inflammation that matters- it's whether it properly settles down after the stroke. Smoking appears to interfere with this recovery, leaving people more vulnerable to memory and thinking problems.

Professor Stuart Allan added: “When the immune system's recovery after stroke doesn't occur as expected, patients appear more likely to experience cognitive difficulties. If future studies confirm interleukin-6 is the cause, we might one day use medications that block it to protect brain health.”

Co-lead author Harry Deijnen from the University of Manchester added: “Though it is clear that more research is needed, these results point towards new opportunities to improve long-term brain health by focusing on the body’s inflammatory recovery after stroke.”

• The work  was funded by the Leducq Foundation, Kennedy Trust, the National Institute for Health and Care Research (NIHR), and the British Heart Foundation. Philanthropic support has also been central to enabling this research. The University is proud to partner with donors in support of this work, including Louis and Amy Wong. Find out more about how supporting 91ֱ�� drives impact across our research here: Challenge Accepted. It was supported by the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)’
• The paper Longitudinal Plasma IL-6 and Post-Stroke Cognitive Outcomes: The Stroke-IMPaCT 91ֱ�� is available DOI:

MEC’s inaugural Researcher Launchpad programme reached an exciting finale on Tuesday 10th March, as early career researchers came together to present the commercial potential of their research to a panel of expert judges.

This marked the culmination of months of entrepreneurial exploration, customer discovery and skills development delivered through the Masood Entrepreneurship Centre’s newest flagship programme.

The final session featured a closed-door pitching round in which researchers unveiled early-stage innovations from across all faculties of the University. The judging panel provided targeted feedback on each idea - assessing commercial viability, clarity of value proposition, customer insight and potential for future development.

Following deliberations, all participants reconvened for the announcement of this year’s award recipients, alongside reflections from the judging panel and a networking session that brought the 2026 cohort together with mentors, programme facilitators and supporters from across the University’s innovation ecosystem.

A new programme built on a strong legacy

Researcher Launchpad represents the next evolution of the highly successful Researcher to Innovator (R2I) initiative, which since 2019 supported dozens of researchers to progress early-stage commercial ideas and secure innovation funding.

Building on this legacy, the enhanced Researcher Launchpad programme now offers an immersive and agile eight-week pre-accelerator designed for PhD and postdoctoral researchers aiming to develop commercial ventures. Throughout the programme, participants learn to articulate the commercial potential of their research, test and validate market assumptions through customer discovery, refine value propositions and routes to market, develop their pitching and communication skills, and build the confidence and entrepreneurial mindset needed to progress their ideas.

Celebrating achievement and enabling next steps

5 awards totalling £20,000 were granted to support the further development of researchers’ ideas. These awards will enable winners to progress activities such as prototype development, market research, technical validation, IP exploration or early engagement with users and stakeholders.

Award Winners

Innovation Enabling Award: £5,000

Foldes

Balint Macsuga (School of Natural Sciences)

"Researcher launchpad has really been a stepping stone for us. The programme equipped us to identify the main challenges of the physiotherapy sector and find the largest gap in market for foldES - our next generational knee-sleeve. We are grateful for the Researcher Launchpad team for their support and can only just recommend participation in the programme."

AI for Multilingualism

Dr Nourhan Heysham (School of Environment, Education and Development

"The Launchpad gave me the structure and confidence to move my idea forward. It provided the space to step back from day-to-day research and think through the opportunity from every angle."

Innovation Enabling Award: £4,000

Curvindiks

Phumza Sokhetye (School of Natural Sciences)

“The programme was a transformative experience that helped me refine my research into a venture-ready project and better understand how it can create real-world and social impact. It provided the skills and confidence needed to communicate the value of my work and take the first steps toward commercialisation.”

Innovation Enabling Award: £3,000

INVIAM: Microbial Recycling of Critical Metals

Patrick King (School of Natural Sciences)

“The MEC Researcher Launchpad is a perfect starting point for researchers who are curious about commercialisation, as well as those who are committed to it and taking their first steps towards that goal.”

Ovasight

Faisal Bala (School of Engineering)

“Two things stand out in this program: the well-paced training that aligns PhD with venture building, and the cash prize awarded upon completion to help you get started.”

Prize winners will also receive expert support and signposting to advanced accelerator programmes and all the participants on the programme will be connected to the wider ecosystem for continued mentoring, guidance and support as they take their research ideas forward.

Looking ahead:

As the Researcher Launchpad programme concludes its inaugural cycle, preparations are already underway for the next cohort. Researchers from all disciplines, whether new to innovation or already exploring commercial routes are encouraged to .

The programme forms part of MEC’s broader Researcher Pathway, a suite of workshops, training and development opportunities designed to strengthen entrepreneurial skills and support researchers to translate their expertise into real-world impact.

Applications to the flagship Venture Further Awards 2026 (VFA) are now open, featuring a brand new “Research-Led Disruption” track. Aligned with the MEC Researcher Pathway, this track supports the critical transition from breakthrough research to commercialisation, helping founders translate innovation into real-world impact.

Full details and application link can be found .

Find out more

To learn about upcoming programmes, workshops and opportunities for researchers, visit: